RC
CAI

Renaissance Capital’s Caris Life Sciences CAI Stock Holding History

Renaissance Capital’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
62,887
+19,403
+45% +$347K 0.62% 33
2026
Q1 		$826K Buy
43,484
+29,055
+201% +$635K 0.6% 30
2025
Q4 		$389K Sell
14,429
-14,031
-49% -$395K 0.28% 36
2025
Q3 		$861K Buy
+28,460
New +$908K 0.48% 29

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Renaissance Capital's CAI Position: Q2 2026 in Review

Renaissance Capital increased its Caris Life Sciences (CAI) stake by 45% in Q2 2026, buying an estimated $347K and bringing the position to 62,887 shares worth $1.12M. The position accounts for 0.62% of the portfolio, ranked #33.

Renaissance Capital first reported a position in CAI in Q3 2025 and has held it in 4 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Renaissance Capital held 62,887 shares of Caris Life Sciences worth $1.12M as of Q2 2026.
  • Renaissance Capital bought 19,403 Caris Life Sciences shares in Q2 2026, an estimated $347K.
  • Caris Life Sciences made up 0.62% of Renaissance Capital's portfolio in Q2 2026, its #33 holding.
  • Renaissance Capital first reported a position in Caris Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Renaissance Capital's 13F filing for Q2 2026, filed 5 Aug 2026.